GILD US3755581036

Report

Delayed Nasdaq - 06/22 04:00:00 pm
67.05	USD		-0.45%

06/22

SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Wins Nod to Market Lymphoma Drug in China; Shares Jump 6% in Hong Kong

06/22

SHANGHAI FOSUN PHARMACEUTICAL : Chinese regulator approves first CAR-T cell therapy in the country

06/22

GILEAD SCIENCES : to Present More Than 70 Abstracts From Diverse Liver Disease Programs at The International Liver Congress 2021

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

06/16/2021	06/17/2021	06/18/2021	06/21/2021	06/22/2021	Date
67.33(c)	67.22(c)	66.61(c)	67.35(c)	67.05(c)	Last
12 938 705	7 015 715	11 464 711	5 310 613	4 796 795	Volume
-1.12%	-0.16%	-0.91%	+1.11%	-0.45%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2021	24 680 M - -
Net income 2021	6 885 M - -
Net Debt 2021	21 984 M - -
P/E ratio 2021	12,7x
Yield 2021	4,19%

Sales 2022	23 833 M - -
Net income 2022	7 010 M - -
Net Debt 2022	17 208 M - -
P/E ratio 2022	12,3x
Yield 2022	4,40%

Capitalization	84 093 M 84 093 M -
EV / Sales 2021	4,30x
EV / Sales 2022	4,25x
Nbr of Employees	13 600
Free-Float	99,9%

More Financials

Company

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular...

Sector

Biotechnology & Medical Research

Calendar

07/28

Earnings Release

More about the company

Ratings of Gilead Sciences, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

All news about GILEAD SCIENCES, INC.

06/22	SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Wins Nod to Market Lymphoma Drug i..	MT
06/22	SHANGHAI FOSUN PHARMACEUTICAL : Chinese regulator approves first CAR-T cell the..	RE
06/22	GILEAD SCIENCES : to Present More Than 70 Abstracts From Diverse Liver Disease ..	AQ
06/22	GILEAD SCIENCES : Veklury Associated With a Reduction in Mortality Rate in Hosp..	AQ
06/22	Mastercard Foundation Appoints Robin Washington to Board of Directors	DJ
06/21	GILEAD SCIENCES : Says Veklury Lowers Mortality Rate in COVID-19 Treatment	MT
06/21	GILEAD SCIENCES : remdesivir reduces COVID-19 mortality risk- data	RE
06/21	GILEAD SCIENCES : Statement on New England Journal of Medicine Publication of P..	AQ
06/21	GILEAD SCIENCES : Veklury® (Remdesivir) Associated With a Reduction in Mortalit..	BU
06/21	GILEAD SCIENCES : to Present More Than 70 Abstracts From Diverse Liver Disease ..	BU
06/17	GILEAD SCIENCES : Kite Partners With Shoreline Biosciences to Develop Cancer Th..	MT
06/17	GILEAD SCIENCES : Kite and Shoreline Biosciences Enter Into Strategic Partnersh..	BU
06/15	UPDATE : Jounce Therapeutics to Get $25 Million From Gilead Sciences After FDA C..	MT
06/15	Jounce Therapeutics Shares Rise 13% on IND Clearance for Cancer Treatment	DJ
06/15	JOUNCE THERAPEUTICS : Set for $25 Million Milestone Payment from Gilead After I..	MT

More news

News in other languages on GILEAD SCIENCES, INC.

06/04	Galapagos publiceert onderzoeksdata over filgotinib
06/03	Covid, accordo Ue per 55.000 dosi trattamento sperimentale Roche-Regeneron
06/02	DGAP-NEWS : MorphoSys übernimmt Constellation -2-
06/02	DGAP-ADHOC : MorphoSys AG übernimmt Constellation -2-
05/18	Galapagos start nieuwe studie naar filgotinib

More news

Analyst Recommendations on GILEAD SCIENCES, INC.

04/30	GILEAD SCIENCES : Morgan Stanley Adjusts Price Target on Gilead Sciences to $83..	MT
04/19	GILEAD SCIENCES : Morgan Stanley Adjusts Price Target on Gilead Sciences to $81..	MT
04/19	GILEAD SCIENCES : Credit Suisse Adjusts Gilead Sciences' Price Target to $69 fr..	MT

More recommendations

Provided by Scoopnest.com

Analysis

Focus: Money, talent flowing into mRNA sector after COVID-19 success